A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the safety and efficacy of a regimen of Avastin plus a
taxane, with or without additional chemotherapy, as first-line treatment in patients with
locally recurrent or metastatic breast cancer. All patients will receive Avastin (10mg/kg iv
every 2 weeks, or 15 mg/kg iv every 3 weeks) plus taxane-based chemotherapy. If taxanes are
contraindicated, alternative chemotherapy (other than anthracyclines or pegylated liposomal
doxorubicin) may be used. The anticipated time on study treatment is until disease
progression, and the target sample size is 500+ individuals.